| [1] Lim HS, Kim SK, Lee HH, et al. Comparison in Adherence to Osteoporosis Guidelines according to Bone Health Status in Korean Adult.J Bone Metab.2016;23(3):143-148.[2] Lin X, Xiong D, Peng YQ, et al. Epidemiology and management of osteoporosis in the People's Republic of China: current perspectives.Clin Interv Aging.2015; 25(10): 1017-1033.[3] Hernlund E, Svedbom A, et al. Osteoporosis in the European Union: medical management, epidemiology and economic burden: A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporosis. 2013;8(1-2):136. [4] Baccaro LF, Conde DM, Costapaiva L, et al. The epidemiology and management of postmenopausal osteoporosis: a viewpoint from Brazil. Clin Interv Aging.2015; 10:583-591.[5] Lötters FJ,Jp VDB,De VF,et al.Current and Future Incidence and Costs of Osteoporosis-Related Fractures in The Netherlands: Combining Claims Data with BMD Measurements.Calcif Tissue Int.2016; 98(3):235-243.[6] Takahara K, Kamimura M, Moriya H, et al. Risk factors of adjacent vertebral collapse after percutaneous vertebroplasty for osteoporotic vertebral fracture in postmenopausal women. Bmc Musculoskelet Disord.2016;17(1):1-7.[7] Chen YC, Lin WC.Can anti-osteoporotic therapy reduce adjacent fracture in magnetic resonance imaging-proven acute osteoporotic vertebral fractures?. Bmc Musculoskelet Disord.2016;17(1):1-5.[8] Hadji P,Jacob L,Kostev K.Gender- and age-related treatment compliance in patients with osteoporosis in Germany.Patient prefer adherence.2016; 10.2379-2385.[9] Chen Z,Arendell L,Aickin M,et al.Hip bone density predicts breast cancer risk independently of Gail score : Results From the Women's Health Initiative.Cancer. 2008; 113(5): 907-15.[10] Mcgraw RL, Riggs JE.Osteoporosis, sedentary lifestyle, and increasing hip fractures: Pathogenic relationship or differential survival bias. Calcif Tissue Int.1994; 55(2):87-89.[11] Shah AD, Shoback D, Lewiecki EM. Sclerostin inhibition: a novel therapeutic approach in the treatment of osteoporosis. Int J Womens Health.2015; 7:565-580.[12] Appelman-Dijkstra NM, Papapoulos SE. Sclerostin Inhibition in the Management of Osteoporosis.Calcif Tissue Int.2016; 98(4):370-380.[13] Yao Q, Ni J, Hou Y, et al.Expression of sclerostin scFv and the effect of sclerostin scFv on healing of osteoporotic femur fracture in rats. Cell Biochem Biophys.2014; 69(2):1-7.[14] Yang X, Deng Z, Wen T, et al. Network Meta-Analysis of Pharmacological Agents for Osteoporosis Treatment and Fracture Prevention. Cell Physiol Biochem. 2016;40(3-4): 781-795.[15] Genant HK, Engelke K,Bolognese MA, et al. Effects of Romosozumab Compared with Teriparatide on Bone Density and Mass at the Spine and Hip in Postmenopausal Women with Low Bone Mass.J Bone Miner Res.2017;32(1):181-187.[16] Lindsay R, Krege JH, Marin F, et al. Teriparatide for osteoporosis: importance of the full course. Osteoporosis Int.2016; 27(8):2395-2410.[17] Hay E,Bouaziz W,Funckbrentano T,et al.Sclerostin and Bone Aging: A Mini-Review. Gerontology.2016;62(6):618-623.[18] Balemans W, Ebeling M, Patel N, et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet.2001; 10(5): 537-543.[19] Balemans W,Van Hul W.Human genetics of SOST.J Musculoskeletal Neuronal Interact.2006; 6(6):355-356.[20] Van HW, Balemans W,Van HE, et al.Van Buchem disease (hyperostosis corticalis generalisata) maps to chromosome 17q12-q21.Am J Hum Genet.1998; 62(2):391-399.[21] Balemans W,Ende JV,Paesalves AF,et al.Localization of the gene for sclerosteosis to the van Buchem disease-gene region on chromosome 17q12-q21. Am J Human Genet.1999; 64(6):1661-1669.[22] Brunkow M. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein.Am J Human Genet.2001; 64(3):577-589.[23] Piters E, Culha C, Moester M, et al. First missense mutation in the SOST gene causing sclerosteosis by loss of sclerostin function. Hum Mutat.2010; 31(7):E1526–E1543.[24] Balemans W,Patel N,Ebeling M,et al.Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J Med Genet.2002; 39(2):91-97.[25] van Bezooijen RL,Roelen BA,Visser A,et al. Sclerostin Is an Osteocyte-expressed Negative Regulator of Bone Formation, But Not a Classical BMP Antagonist. J Exp Med 2004; 199(6): 805-814.[26] Semënov M,Tamai K,He X.SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor.J Biol Chem.2005; 280(29): 26770-26775.[27] Semenov M V, He X. LRP5 mutations linked to high bone mass diseases cause reduced LRP5 binding and inhibition by SOST.J Biol Chem.2006; 281(50):38276-38284.[28] Li X, Zhang Y, Kang H, et al. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling.J Biol Chem.2005; 280(20):19883-19887.[29] Chang MK, Kramer I,Keller H,et al.Reversing LRP5-dependent osteoporosis and SOST deficiency-induced sclerosing bone disorders by altering WNT signaling activity. J Bone Miner Res.2014; 29(1):29-42.[30] Yorgan TA,Peters S,Jeschke A,et al.The Anti-Osteoanabolic Function of Sclerostin Is Blunted in Mice Carrying a High Bone Mass Mutation of Lrp5. J Bone Miner Res.2015; 30(7): 1175-1183.[31] Wang Y, Li YP, Paulson C,et al.Wnt and the Wnt signaling pathway in bone development and disease. Front Biosci (Landmark Ed). 2014;19:379-407.[32] Rudnicki MA, Williams BO. Wnt signaling in bone and muscle. Bone.2015; 80:60-66.[33] Li X, Ominsky MS, Warmington KS, et al.Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res.2009; 24(4):578-588.[34] Ominsky MS,Vlasseros F,Jolette J,et al.Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res.2010; 25(5):948-959.[35] Virk MS, Alaee F, Tang H, et al.Systemic Administration of Sclerostin Antibody Enhances Bone Repair in a Critical-Sized Femoral Defect in a Rat Model.J Bone Joint Surg Am.2013; 95(8):694-701.[36] Padhi D, Jang G, Stouch B, et al. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res.2011; 26(1):19-26.[37] McClung MR,Grauer A,Boonen S,et al.Romosozumab in Postmenopausal Women with Low Bone Mineral Density.N Enl J Med.2014;370:412-420.[38] Cosman F,Crittenden DB,Adachi JD,et al.Romosozumab Treatment in Postmenopausal Women with Osteoporosis.New Engl J Med.2016; 375(16):1532-1543.[39] Mccolm J,Hu L,Womack T,et al.Single- and multiple-dose randomized studies of blosozumab, a monoclonal antibody against sclerostin, in healthy postmenopausal women. J Bone Miner Res.2014; 29(4):935–943.[40] Recker R,Benson C,Matsumoto T,et al.A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density.J Bone Miner Res.2015; 30(2):216-224.[41] Recknor CP, Recker RR, Benson CT, et al.The Effect of Discontinuing Treatment With Blosozumab: Follow-up Results of a Phase 2 Randomized Clinical Trial in Postmenopausal Women With Low Bone Mineral Density.J Bone Miner Res. 2015; 30(9):1717-1725.[42] Claire MN, Patton D,Hayes JS.Sclerostin Antibody Therapy for the Treatment of Osteoporosis: Clinical Prospects and Challenges.J Osteoporosis.2016;2016(6217286).[43] Sugiyama T, Torio T, Miyajima T, et al. Romosozumab and Blosozumab: Alternative Drugs of Mechanical Strain-Related Stimulus Toward a Cure for Osteoporosis. Front Endocrinol (Lausanne). 2015; 6:54.[44] Florio M,Gunasekaran K,Stolina M,et al.A bispecific antibody targeting sclerostin and DKK-1 promotes bone mass accrual and fracture repair. Nat Commun. 2016;7:11505.[45] Boschert V, Frisch C, Back JW, et al.The sclerostin- neutralizing antibody AbD09097 recognizes an epitope adjacent to sclerostin's binding site for the Wnt co-receptor LRP6. Open Biol. 2016;6(8). pii: 160120. [46] Basha G, Ordobadi M, Scott W R, et al. Lipid Nanoparticle Delivery of siRNA to Osteocytes Leads to Effective Silencing of SOST and Inhibition of Sclerostin In Vivo. Molecular Therapy- Nucleic Acids.2016; 5(9):e363.[47] Armamento-Villareal R,Sadler C,Napoli N,et al.Weight loss in obese older adults increases serum sclerostin and impairs hip geometry but both are prevented by exercise training. J Bone Miner Res.2012; 27(5):1215-1221.[48] Gombos GC, Bajsz V, Pék E, et al. Direct effects of physical training on markers of bone metabolism and serum sclerostin concentrations in older adults with low bone mass. Bmc Musculoskelet Disord.2016;17(1):1-8.[49] Ardawi MS, Rouzi AA, Qari MH. Physical Activity in Relation to Serum Sclerostin, Insulin-Like Growth Factor-1, and Bone Turnover Markers in Healthy Premenopausal Women: A Cross-Sectional and a Longitudinal Study.J Clin Endocrinol Metab.2012;97(10):3691-3699.[50] Compton JT, Lee FY. A review of osteocyte function and the emerging importance of sclerostin.J Bone Joint Surg Am.2014; 96(19):1659-1668.[51] Spatz JM, Fields EE, Yu EW, et al.Serum sclerostin increases in healthy adult men during bed rest.J Clin Endocrinol Metabo.2012; 97(9):1736-1740.[52] Zagrodna A,Jó?ków P,M?dra? M,et al.Sclerostin as a novel marker of bone turnover in athletes. Biol Sport.2016; 33(1): 83-87.[53] Christen P, Ito K, Ellouz R, et al. Bone remodelling in humans is load-driven but not lazy. Nat Commun.2014; 5(5): 4855-4855.[54] Galea GL, Lanyon LE, Price JS. Sclerostin's role in bone's adaptive response to mechanical loading.Bone.2017; 96: 38-44.[55] Robling AG, Niziolek PJ, Baldridge LA,et al.Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin.J Biol Chem.2008; 283(9):5866-5875.[56] Silverman SL.Sclerostin. J Osteoporos.2010;2010:941419[57] Gupta A,March L.Treating osteoporosis.Australian Prescriber. 2016;39(2):40-46. [58] Thouverey C,Caverzasio J.Sclerostin inhibits osteoblast differentiation without affecting BMP2/SMAD1/5 or Wnt3a/β-catenin signaling but through activation of platelet-derived growth factor receptor signaling in vitro. Bonekey Rep.2015; 4:757. |
.jpg)
文题释义：
骨硬化蛋白(Sclerostin)：是SOST基因表达的一种分泌蛋白，在骨细胞产生后转运到骨表面参与骨代谢的调节，sclerostin与共受体LRP5/6结合抑制Wnt/β-catenin通路，降低成骨细胞的骨生成作用，导致骨密度降低、骨脆性增加。
AMG785(Romosozumab)：人类来源的sclerostin单克隆抗体，用于骨质疏松治疗的第Ⅲ期临床试验已经结束，结果显示其能显著增加腰椎和髋部的骨密度，促进骨生成，抑制骨吸收，且有很好的耐受性。
.jpg)
文题释义：
骨硬化蛋白(Sclerostin)：是SOST基因表达的一种分泌蛋白，在骨细胞产生后转运到骨表面参与骨代谢的调节，sclerostin与共受体LRP5/6结合抑制Wnt/β-catenin通路，降低成骨细胞的骨生成作用，导致骨密度降低、骨脆性增加。
AMG785(Romosozumab)：人类来源的sclerostin单克隆抗体，用于骨质疏松治疗的第Ⅲ期临床试验已经结束，结果显示其能显著增加腰椎和髋部的骨密度，促进骨生成，抑制骨吸收，且有很好的耐受性。